Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell Engagers
09. Dezember 2024 05:00 ET
|
Medigene AG
Planegg/Martinsried, December 9, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene Presents Data on an Innovative IFN-γ Biosensor Technology at SITC 2024
12. November 2024 07:00 ET
|
Medigene AG
Planegg/Martinsried, November 12, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene Presents Latest Data on UniTope & TraCR Technology at PEGS and SITC 2024
11. November 2024 07:00 ET
|
Medigene AG
Planegg/Martinsried, November 11, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene Presents Unique Approach for Use of Optimal T Cell Receptors in TCR-Guided Modalities at Cell 2024
08. November 2024 09:30 ET
|
Medigene AG
Members of Medigene management as expert speakers, Prof. Dolores Schendel, Chief Scientific Officer and Kirsty Crame, MD, Vice President, Clinical Strategy & DevelopmentPresentations and seminars...
Medigene to Present at Upcoming Investor Conferences
29. Oktober 2024 06:30 ET
|
Medigene AG
Planegg/Martinsried, October 29, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene AG reports Financial Results and Business Update for Q3 2024
24. Oktober 2024 01:30 ET
|
Medigene AG
Planegg/Martinsried, October 24, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene presents UniTope and TraCR a universal detection system for 3S recombinant TCRs at ASGCT 2024
17. Oktober 2024 05:30 ET
|
Medigene AG
Planegg/Martinsried, October 17, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene to Present at Upcoming Scientific Conferences
16. Oktober 2024 05:30 ET
|
Medigene AG
Planegg/Martinsried, October 16, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene will Present at ASGCT 2024 and Host R&D Event
02. Oktober 2024 09:00 ET
|
Medigene AG
Planegg/Martinsried, October 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene to Host Virtual R&D Event on Medigene’s Optimal 3S TCRs for TCR-Guided Precision Immunotherapies
16. September 2024 08:30 ET
|
Medigene AG
Planegg/Martinsried, September 16, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...